The antibody response to the COVID-19 vaccine and infection among Egyptian patients with hematological malignancies | ||||
| Microbes and Infectious Diseases | ||||
| Articles in Press, Accepted Manuscript, Available Online from 25 February 2025 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mid.2025.354542.2474 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sara El-Sayed Abd El-Ghani   1; Eman Rafat Mohammed Abd El-Hafez1; Mervat Mattar1; Amal Mohamed Sayed Hassan2; Marwa Salah Mohamed1
| ||||
| 1Department of Internal Medicine, Clinical Hematology Unit, Kasr Al-ainy Faculty of Medicine, Cairo University, Cairo, Egypt | ||||
| 2Department of Clinical and Chemical Pathology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt. | ||||
| Abstract | ||||
| Background: The COVID-19 pandemic has complicated health services for cancer patients. Patients with hematological malignancies (HMs) are at high risk for COVID-19-related complications, resulting in elevated mortality rates. Vaccination serves as a crucial strategy for the primary prevention of COVID-19, particularly for high-risk patients, to mitigate morbidity and mortality associated with the virus. Patients with HMs demonstrate diminished seroconversion rates post-COVID-19 infection or vaccination compared to other cancer patients and are more vulnerable to viral infections. In addition, COVID-19 vaccine response in HM patients is inadequate, attributed to factors such as hypogammaglobulinemia, advanced age, ongoing treatment, and previous administration of immunosuppressive drugs. Aim: This study aimed to evaluate the antibody levels to COVID-19 infection and vaccination among patients with HMs. Methods: Eighty-six Egyptian patients aged more than 18 years were recruited from the Kasr Al-Ainy Hospital outpatient clinic with different HMs. The detection of immunoglobulin (IgG to COVID-19) titers in vaccinated and unvaccinated patients and the detection of COVID-19 anti-spike IgM antibodies in vaccinated patients were performed. Results: Most recruited patients (83.7% of the study group) developed a positive antibody response to COVID-19 infection. Among 43 vaccinated patients, anti-spike IgM was assessed, revealing a positive titer of 86%. Our findings indicate that patients with lymphoma exhibited the lowest antibody level to COVID-19 infection, whereas patients with acute leukemia (ALL) demonstrated the highest level. Conclusion: Vaccination is highly advised for individuals with HMs. Further studies involving a larger patient population and various types of HMs are recommended. | ||||
| Keywords | ||||
| Antibody; COVID-19; Vaccination; Hematological malignancies | ||||
|
Statistics Article View: 116 |
||||
